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Abstract: Neuromuscular blockade, induced by neuromuscular blocking agents, has allowed 
prescribed immobility, improved surgical exposure, optimal airway management conditions, 
and facilitated mechanical ventilation. However, termination of the effects of neuromuscular 
blocking agents has, until now, remained limited. A novel cyclodextrin encapsulation process 
offers improved termination of the paralytic effects of aminosteroidal non-depolarizing neu-
romuscular blocking agents. Sugammadex sodium is the ﬁ  rst in a new class of drug called 
selective relaxant binding agents. Currently, in clinical trials, sugammadex, a modiﬁ  ed gamma 
cyclodextrin, has shown consistent and rapid termination of neuromuscular blockade with few 
side effects. The pharmacology of cyclodextrins in general and sugammadex in particular, 
together with the results of current clinical research are reviewed. The ability of sugammadex 
to terminate the action of neuromuscular blocking agents by direct encapsulation is compared to 
the indirect competitive antagonism of their effects by cholinesterase inhibitors. Also discussed 
are the clinical implications that extend beyond fast, effective reversal, including numerous 
potential peri-operative beneﬁ  ts.
Keywords: modiﬁ  ed cyclodextrin, selective relaxant binding agent (SRBA), sugammadex, 
encapsulation, muscle relaxants, neuromuscular blockade reversal
Introduction
Since the introduction of curare, neuromuscular blocking agents (NMBAs) have allowed 
us to immobilize patients and improve medical and surgical interventions (Bohm 1912; 
Grifﬁ  th and Johnson 1942). The synthesis and development of new NMBAs have pro-
duced agents that are close to ideal. Unfortunately, NMBA reversal agents have not been 
improved upon. The cholinesterase inhibitor drugs ﬁ  rst used to reverse curare currently 
remain the standard for reversing all NMBAs. The indirect action of cholinesterase 
inhibitors is limited in its ability to reverse neuromuscular blockade, and is associated 
with numerous side effects. A new class of drugs, selective relaxant binding agents 
(SRBAs), has the potential to overcome the limitations of cholinesterase inhibitors.
The ﬁ  rst SRBA to be introduced is sugammadex (sugammadex sodium, generic, 
Organon International, a part of Schering-Plough Corporation, Oss, The Netherlands), 
a modiﬁ  ed gamma cyclodextrin (CD) with the chemical formula C72H104Na8O48S8 cur-
rently in phase III clinical trials. Unlike the cholinesterase inhibitors, which indirectly 
and competitively antagonize NMBAs by increasing acetylcholine (ACh), sugammadex 
acts by directly encapsulating, binding, and inactivating NMBAs (Figure 1).
Conventional neuromuscular blockade reversal
Cholinesterase inhibitors act indirectly against the effects of NMBAs by inactivating 
the enzyme acetylcholinesterase (AChE) which is responsible for the breakdown Drug Design, Development and Therapy 2008:2 50
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of ACh. Acetylcholine levels then increase dramatically, 
displacing the NMBA molecules from the nicotinic 
receptors. Thus, NMBAs are not inactivated or broken 
down by cholinesterase inhibitors. They are only displaced 
from the site of action, the nicotinic receptor. The two 
cholinesterase inhibitors most often used in clinical practice 
are edrophonium and neostigmine, which form reversible, 
non-covalent attachments to the anionic site or esteratic 
site on the AChE molecule. Their duration of action is 
60 minutes or less. AChE activity returns to normal after 
the detachment and metabolism of cholinesterase inhibi-
tors. The temporary increase in ACh then returns to normal 
levels. NMBA molecules still present after normalization 
of ACh levels may successfully compete for the nicotinic 
receptor and re-exert their neuromuscular blocking effects. 
Re-currence of paralysis (recurarization) is usually only 
a risk with long-acting NMBAs, although it has been 
reported with intermediate duration NMBAs (Singh et al 
1982; Baillard et al 2000; Debaene et al 2003). Similarly, 
incomplete displacement (partial reversal) of NMBAs by 
cholinesterase inhibitors may result in residual paralysis 
(Hayes et al 2001; Appelboam et al 2003; Kirkegaard et al 
2002; Murphy et al 2005; Murphy 2006).
Residual paralysis
The risks of residual paralysis include: dysphagia, 
hypoventilation, weakened hypoxic drive, impaired 
coughing, compromised pharyngeal and laryngeal function 
and pulmonary complications (Berg et al 1997; Eriksson 
1999; Tramer and Fuchs-Buder 1999; Eikermann et al 2006). 
The primary concern in patients with residual paralysis is 
airway protection and adequate ventilation. Atelectesis may 
occur intra-operatively due to patient position, positive pres-
sure ventilation, and hypoventilation, and is compounded in 
the post-operative period by any degree of residual paralysis. 
The residual presence of volatile anesthetics, benzodiaz-
epines, and narcotics in the tissue compartments contribute 
to post-operative hypoventilation. Hypoventilation coupled 
with residual paralysis places a patient in less than optimal 
circumstances (Eriksson 1999).
Another drawback of cholinesterease inhibitors is their 
effects on ACh levels are not limited to the nicotinic junc-
tion. Generalized increases in ACh throughout the body 
causes pronounce side effects. Parasympathetic effects pre-
dominate when ACh is increased, leading to cardiovascular, 
pulmonary, gastrointestinal, and neurological sequelae. 
Side effects of cholinesterase inhibitors include: bradycar-
dia, bronchospasm, increased airway secretions, nausea, 
vomiting, increased peristalsis, increased urination, muscle 
cramps/spasms, miosis, vision disturbances, and convul-
sions (Neostigmine Package Insert 2002). Anti-cholinergic 
drugs are therefore given concomitantly with cholinesterase 
inhibitors to attenuate their parasympathetic effects. These 
anti-cholinergic drugs are partially effective in this respect 
but exert their own side effects including: cardiac arrhyth-
mias, tachycardia, QT prolongation, nausea, vomiting, 
constipation, urinary retention, severe allergic reactions, dry 
mouth, mydriasis, and confusion (Glycopyrrolate Package 
Insert 2002).
In contrast, a new concept of NMBA inactivation by 
SRBA encapsulation rather than competitive antagonism has 
been shown to be fast, effective, and safe for the reversal of 
neuromuscular blockade in clinical trials to date with few 
side effects. This encapsulation process is enabled by the 
unique characteristics of CDs.
Cyclodextrin characteristics
Natural CDs are found in nature wherever starch sources, 
bacteria, and appropriate environmental conditions exist. 
The glucopyranose units of amylose starch are enzymati-
cally restructured by bacteria such as Bacillus macerans, 
creating the natural CDs (Szejtli 2004). The natural CDs 
consist of rings of six, seven, or eight glucopyranose units 
named alpha, beta, and gamma, respectively (Figure 2). The 
glucopyranose units are attached by alpha 1–4 linkages in a 
circular arrangement. This arrangement creates a truncated 
cone that points the hydroxyl groups outward along the rims 
Figure 1 Crystal spectroscopy image of sugammadex encapsulating a rocuronium mol-
ecule. Reprinted with permission from Zhang M-Q. 2003. Drug-speciﬁ  c cyclodextrins: 
The future of rapid neuromuscular block reversal? Drugs Future, 28: 347–54. Copyright© 
2003 Prous Scientiﬁ  c and Organon USA, a part of Schering-Plough Corporation. Drug Design, Development and Therapy 2008:2 51
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while directing the alpha 1–4 linkages inward (Figure 3). 
The narrow opening is called the primary face, and the larger 
opening is called the secondary face. The negatively charged 
hydroxyl groups lining the primary and secondary faces are 
responsible for the water solubility of these molecules. The 
interior of the CD is lined by the carbon atoms and alpha 
1–4 linkages creating a lipophilic cavity. The steric nature of 
CDs creates a water soluble molecule that possesses a cavity 
capable of surrounding and binding a lipophilic molecule. 
The main pharmacologic beneﬁ  t extracted from this structural 
arrangement is encapsulation of appropriately sized lipophilic 
molecules or drugs and the promotion of aqueous solubility 
(Welliver 2007).
Historically, CDs have been considered excipients 
(inert adjuncts) lacking pharmacologic activity but useful 
for improving the formulation of other active compounds 
(Thompson and Chaubal 2002; Loftsson et al 2005). The 
two key characteristics of CDs   – lipophilic molecule encap-
sulation and aqueous solubility – have multiple beneﬁ  cial 
applications. For example, CD encapsulation of lipophilic 
drugs, which are difﬁ  cult to solubilize, allows their dissolu-
tion in water, which is biologically better tolerated than the 
organic solvents currently used, such as benzyl alcohol and 
propylene glycol (MacPherson 2001). The pharmacologic 
beneﬁ  ts of CD solubilization have been explored and applied 
successfully with many drug formulations throughout the 
world (Challa et al 2005). The solubilization characteristics 
of CDs, coupled with biological tolerance, make them desir-
able replacements for other organic solvents.
Although CDs possess aqueous solubility and an afﬁ  nity for 
lipophilic molecules, the relative potency of these characteristics 
varies between different CDs. Close size approximation of lipo-
philic molecules to their corresponding CD is necessary to allow 
non-covalent thermodynamic interactions to occur promoting 
the formation of an inclusion complex. The approximate cavity 
sizes of the natural CDs are: gamma (0.8 nm)  beta (0.6 nm) 
 alpha (0.5 nm) (Welliver 2007). Once inside a CD cavity, 
thermodynamic attractions – including electrostatic interaction, 
van der Waals interaction, hydrophobic interaction, hydrogen 
bonding, release of conformational strain, exclusion of cavity-
bound high-energy water, and charge-transfer interaction – may 
contribute to the formation of the inclusion complex (Liu and 
Guo 2002). An inclusion complex, also known as a host-guest 
assembly, is the newly formed molecular entity of a CD and 
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Figure 2 Naturally occurring cyclodextrins. From left to right: alpha, beta, and gamma. Sites of modiﬁ  cation for the creation of sugammadex are the peripheral 6th carbon 
hydroxyl groups on the gamma cyclodextrin. Reproduced with permission from Welliver M. 2007. Update for nurse anesthetists. Part 3. Cyclodextrin introduction to anes-
thesia practice: form, function, and application. AANA J, 75:289–96. Copyright© 2007 American Association of Nurse Anesthetists.
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Figure 3 Structural arrangement of glucopyranose units in a gamma CD, showing 
primary and secondary rim hydroxyl groups. Reproduced with permission from 
Welliver M. 2007. Update for nurse anesthetists. Part 3. Cyclodextrin introduction to 
anesthesia practice: form, function, and application. AANA J, 75:289–96. Copyright© 
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its encapsulated lipophilic molecule. Modification of the 
natural CDs allows improvement of their aqueous solubility 
and thermodynamic attractions for a particular guest molecule. 
The sites available for CD modiﬁ  cation are on the 2nd, 3rd, and 
6th carbon atoms of the glucopyranose sub-units (Figure 3). 
Numerous substituent atoms or groups may be placed on any 
or all of these sites improving a CD’s afﬁ  nity for a particular 
molecule (Szente and Szejtli 2002). The ability to improve upon 
the base characteristics of natural CDs has led to the discovery 
of a CD that promises the unique drug effect of NMBA encap-
sulation with resultant termination of the paralytic effect.
Discovery of the modiﬁ  ed 
cyclodextrin sugammadex
The impetus for discovery of the modiﬁ  ed gamma CD 
sugammadex was the desire to improve the solubility of 
the NMBA rocuronium (Zhang 2003). Rocuronium is a 
non-depolarizing NMBA with a steroidal backbone that is 
commercially prepared in an aqueous solution adjusted to a 
pH of 4.0 (Rocuronium package insert 2007). Researchers 
at Organon Laboratories (New House, UK) wanted to solu-
bilize rocuronium without the acidic mannitol phosphate 
buffer solvent used in the current formulation. A different 
rocuronium formulation was considered desireable in order to 
eliminate the acidic pH as an extraneous variable in in vitro 
experiments of the smooth muscle effects of rocuronium 
(Bom and Hope 2007). The exploration of suitable solvents 
led to CDs, which have been known and used to solubilize 
lipophilic molecules for over 100 years (Szetjtli 2004).
Understanding the potential to achieve CD encapsulation 
speciﬁ  c for rocuronium, researchers explored many modiﬁ  ca-
tions of the alpha, beta, and gamma CDs (Adam et al 2002; 
Tarver et al 2002) The candidate CD chosen to solubilize 
rocuronium was the modiﬁ  ed gamma CD Org 25969 (sugam-
madex). Sugammadex is a modiﬁ  ed gamma CD with every 
6th carbon hydroxyl group substituted with a thioether linked 
to a carboxyl group (Figure 4). The thioether linkages extend 
the cavity length allowing complete encapsulation of the 
rocuronium molecule while increasing the area over which 
thermodynamic attractions can occur (Bom et al 2002a; Bom 
et al 2002b; Zhang 2003) A secondary beneﬁ  t provided by 
the negatively charged carboxyl groups is an increased aque-
ous solubility of the sugammadex molecule (Zhang 2003) 
(Figure 5). X-ray crystallography has shown very close size 
compatibility between sugammadex and the rocuronium mol-
ecule (Bom et al 2002a) Furthermore, it was found to be one 
of the most stable complexes of a CD and its guest molecule, 
with an association constant (Ka) of 1.8 × 107 M−1 (Bom et al 
2002a) Many unrelated drug/CD complexes studied previously 
have averaged Kas of 1 × 101 M−1 to 2 × 104 M−1 (Challa et al 
2005). The discovery of sugammadex’s extremely high bind-
ing afﬁ  nity for rocuronium changed the research focus from in 
vitro drug solubilization to the novel concept of in vivo drug 
extraction (Bom et al 2007). The new concept of encapsulation 
termination of the effects of NMBAs was born.
The high lipophilic binding afﬁ  nity of sugammadex raised 
concerns about potential undesirable binding to endogenous and 
exogenous steroidal compounds. These concerns were addressed 
during early studies. Zhang found over 40 lipophilic, steroidal, 
and non steroidal drugs typically given during an anesthetic case 
had afﬁ  nities with sugammadex that ranged from 120–700 times 
less than that of rocuronium (Zhang 2003). These drugs include 
induction agents (propofol, thiopenthane), narcotics (fentanyl, 
remifentanyl), antibiotics (vancomycin, gentamycin), bron-
chodilators (salbutamol, aminophyline), cardiovascular drugs 
(atropine, digoxin, ephedrine, phentolamine, verapamil), and 
steroids (cortisone, hydrocortisone) (Zhang 2003). Clinical stud-
ies also showed no evidence of interaction with or alteration of 
the volatile inhalation anesthetic sevoﬂ  urane or the intravenous 
anesthetic propofol (Vanacker et al 2007). Elsewhere, it was 
demonstrated that propanolol and isoprenaline did not modify 
the action of sugammadex (Bom and Hope 2007). Thus, sugam-
madex has high selectivity for the aminosteroidal NMBAs.
Mechanism of action
Sugammadex is unique in its application, since CDs have 
been used to encapsulate lipophilic molecules in vitro in 
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order to increase solubilization for improved drug delivery. 
Sugammadex is the ﬁ  rst CD created to perform its own drug 
effect. The process of sugammadex reversal of NMBA effects 
can be broken down into two component parts, direct molecular 
encapsulation (Figure 6) and mass extraction of NMBAs from 
the nicotinic junction into the plasma (Figure 7). Sugammadex 
is administered intravenously and remains in the plasma without 
diffusing or being transported to other compartments. In the 
plasma, sugammadex encapsulates and non-covalently binds 
amonosteroidal NMBAs with a one-to-one ratio. The specif-
ics of this encapsulation process have been the focus of early 
studies. Using microcrystalography, Bom determined that all 
four steroidal rings of the rocuronium molecule lie in close 
approximation to the lipophilic cavity of the sugammadex mol-
ecule, with the quaternary containing ring (D) surrounded by the 
carboxyl groups (Bom et al 2002a). It was believed that ther-
modynamic interactions occurring between the sugammadex 
cavity and the steroidal backbone of the rocuronium molecule, 
along with the carboxyl groups attractions for rocuronium’s 
tertiary ammonium accounted for its total high binding afﬁ  nity 
(Adam et al 2002; Zhang 2003).
The plasma encapsulation of NMBA molecules prevents 
their diffusion into the peripheral compartment for attachment 
to nicotinic ACh receptors. In addition, NMBA molecules 
already attached to extracellular nicotinic receptors, causing 
neuromuscular blockade are rapidly drawn into the plasma 
and encapsulated. This removal of NMBA molecules from 
nicotinic ACh receptors occurs because of the concentration 
gradient created by sugammadex binding of the NMBAs in 
the plasma (Epemolu et al 2003). That is, the shift to a low 
concentration of unbound NMBA molecules in the plasma 
causes the higher concentration of extracellular NMBA mol-
ecules to detach from the ACh receptors and diffuse into the 
plasma. Once back in the plasma, these NMBA molecules 
are quickly encapsulated and bound by sugammadex. This 
process occurs rapidly, restoring motor function.
The two-fold process of one-to-one encapsulation/
binding in the plasma and the concentration gradient-
mediated extraction of NMBAs from the nicotinic ACh 
receptors results in fast and effective termination of neuro-
muscular blockade by sugammadex. The ability of sugamma-
dex to encapsulate and reverse the effects of aminosteroidal 
NMBAs varies between agents. Sugammadex reverses 
rocuronium greater than vecuronium and much greater than 
pancuronium (Alvarez-Gomez et al 2007; Decoopman et al 
2007; Duvaldestin et al 2007).
Preclinical studies
An overview of the research shows the development and pro-
gression of a safe and efﬁ  cacious reversal drug that is poised to 
enable dramatic improvements in the management of neuro-
muscular blockade. Animal studies conﬁ  rmed the high afﬁ  nity 
of sugammadex for both rocuronium and vecuronium and, to a 
lesser extent, pancuronium with the ability to terminate NMBA 
effects under multiple conditions. (Welliver 2006). Mason 
successfully reversed rocuronium- and vecuronium-induced 
Figure 5 Aqueous inclusion complex of sugammadex-rocuronium.Drug Design, Development and Therapy 2008:2 54
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neuromuscular blockade in guinea pigs with sugammadex 
1 mg/kg in less than 1 minute (Mason and Bom 2001). 
Profound neuromuscular block induced by rocuronium 500 
μg/kg in Rhesus monkeys was successfully performed by 
de Boer using 2.5 mg/kg sugammadex (de Boer et al 2006). 
Sugammadex reversal of rocuronium was unaffected by pH 
changes in guinea pigs or renal impairment in cats (Bom et al 
2002c; Bom et al 2003).
Clinical studies
Phase I studies
Human studies of sugammadex were first performed 
by Gijsenbergh in 29 healthy male volunteers. All were 
anesthetized and had neuromuscular blockade induced by 
rocuronium. Either placebo or sugammadex, in doses ranging 
from 0.1–8.0 mg/kg, were given, and both time and degree 
of reversal were recorded. Sugammadex 8.0 mg/kg reversed 
rocuronium-induced blockade in 1 minute, compared to 52 
minutes with placebo. The investigators concluded that effec-
tive and safe reversal of rocuronium-induced neuromuscular 
blockade could be achieved with sugammadex. (Gijsenbergh 
et al 2005).
Phase II studies
A phase II study also demonstrated safe reversal of 
rocuronium-induced neuromuscular blockade of 2 hours 
or greater duration (Shields et al 2006). In this study of 30 
anesthetized patients age 18 years, ASA class I-III, sugam-
madex was administered at doses of 0.5–6.0 mg/kg. At doses 
of 1.0 mg/kg and above, sugammadex effectively reversed 
the effects of rocuronium in a dose-dependant fashion within 
4 minutes (Shields et al 2006). Two studies in 87 patients 
age 18–87 years, ASA class I-III, explored the use of sugam-
madex for reversal of high-dose rocuronium (1.0 and 1.2 
mg/kg) (Khunl-Brady et al 2005; Rex et al 2005). Sugam-
madex (2–16 mg/kg) was administered at 3 and 15 minutes 
after rocuronium administration. The average time to reversal 
(TOF 0.9) with 8.0 mg/kg sugammadex was 3 minutes at 
both time intervals with both doses of rocuronium. It was 
concluded that there was a clear dose-response relationship 
in terms of time to recovery with sugammadex (Khunl-Brady 
et al 2005; Rex et al 2005) de Boer also found profound 
rocuronium-induced (1.2 mg/kg) neuromuscular blockade 
given with propofol and opioid anesthesia of greater than 
90 minutes duration was effectively reversed by sugammadex 
in a dose dependent manner in 45 patients aged 18–64 years, 
ASA class I-II (de Boer et al 2007).
Studies of sugammadex for the reversal of shallow 
vecuronium-induced neuromuscular blockade have also 
shown a dose-dependent time to full reversal. Puhringer 
reversed both vecuronium- and rocuronium-induced neuro-
muscular blockade in 100 patients, age 20–65 years, ASA 
class I-III (Puhringer et al 2007). Sugammadex doses of 
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2.0 mg/kg for rocuronium and 4.0 mg/kg for vecuronium 
effectively reversed shallow neuromuscular blockade 
(TOF 2/4) in 3 minutes or less. In another study, profound 
vecuronium-induced neuromuscular blockade (PTC 1–2) 
was effectively reversed by sugammadex 4.0 mg/kg in an 
average time of 4.5 minutes (Lemmens et al 2007). Dose-
dependent reversal of both rocuronium- and vecuronium-
induced profound neuromuscular blockade by sugammadex 
was also observed by Duvaldestin in a study of 102 patients, 
age 21–64 years, ASA class I-III (Duvaldestin et al 2007). 
Sugammadex 2.0 mg/kg reversed profound rocuronium-
induced neuromuscular blockade (PTC 1–2) in 3.5 minutes 
or less, while a greater dose of 4.0 mg/kg was required to 
reverse vecuronium-induced profound neuromuscular block-
ade within the same amount of time.
In addition to the intermediate duration NMBAs 
rocuronium and vecuronium, the effects of the long acting 
NMBA pancuronium have also been successfully reversed 
by sugammadex (Decoopman et al 2007). In this study of 20 
patients, age 20–81 years, ASA class I-III, shallow (TOF 2/4) 
pancuronium-induced neuromuscular blockade was effec-
tively reversed in less than 3 minutes with a sugammadex 
dose of 4.0 mg/kg. The authors concluded that sugammadex 
had a “good safety proﬁ  le”. Interestingly, a signiﬁ  cant dose-
response relationship was not shown in this study. The effec-
tiveness of sugammadex for the reversal of pancuronium, in 
addition to rocuronium and vecuronium, is signiﬁ  cant in light 
of the limitations of cholinesterase inhibitors.
The efﬁ  cacy of sugammadex for the reversal of neuromus-
cular blockade has been compared to that of the cholinesterase 
inhibitor reversal drugs neostigmine and edrophonium. In one 
study the speed and effectiveness of sugammadex (4.0 mg/kg) 
for reversal of profound vecuronium-induced neuromuscular 
blockade (PTC 1–2) was compared to that of neostigmine (70 
μg/kg) (Lemmens et al 2007). With neostigmine, the average 
reversal time to a TOF ratio of 0.9 was 66.2 minutes compared 
to an average time of 4.5 minutes with sugammadex. Another 
study comparing sugammadex (4.0 mg/kg) and neostigmine 
(70 μg/kg) for reversal of profound rocuronium-induced neu-
romuscular blockade (PTC 1–2) also observed a much faster 
return to a TOF ratio of 0.9 with sugammadex (2.9 minutes) 
than neostigmine (50.4 minutes) (Jones et al 2007).
The results of these phase II clinical studies have 
consistently demonstrated that sugammadex achieves fast 
and effective reversal of various degrees and durations 
of rocuronium- and vecuronium-induced neuromuscular 
blockade. Shallow pancuronium-induced neuromuscular 
blockade has also been effectively reversed (Deccopman 
et al 2007). Comparisons with cholinesterase inhibitors have 
shown faster and more thorough reversal accomplished with 
sugammadex with an improved safety proﬁ  le (Lemmens et al 
2007; Jones et al 2007).
Phase III studies
In a phase III study in 100 patients, Alvarez-Gomez reported 
faster reversal of vecuronium using sugammadex 2.0 mg/kg 
compared to neostigmine 50 μg/kg (Alvarez-Gomez et al 
2007). The median time for reversal of shallow (TOF 2/4) 
vecuronium-induced neuromuscular blockade to a recovery 
of 0.9 TOF ratio was 2.1 minutes for sugammadex and 
18.9 minutes for neostigmine. In another study, reversal of 
moderately profound rocuronium-induced neuromuscular 
blockade was also found to be faster with sugammadex 
4.0 mg/kg (average 1.78 minutes) verses edrophonium-
atropine (average 5.51 minutes) and neostigmine-glycopyr-
rolate (average 17.4 minutes) (Sacan et al 2007). All patients 
reversed with sugammadex achieved full reversal to a TOF 
ratio of 0.9. Only 10% of the edrophonium-atropine reversed 
patients and 25% of the neostigmine-glycopyrrolate reversed 
patients achieved full reversal within 30 minutes. Interest-
ingly, all patients were able to perform a 5-second head lift 
after all reversal drugs. The sugammadex group experienced 
signiﬁ  cantly lower incidences of increased heart rate and 
dry mouth.
Additional comparison of sugammadex to conventional 
cholinesterase inhibitor reversal therapy has demonstrated a 
faster time to full reversal of rocuronium- and vecuronium-
induced neuromuscular blockade by sugammadex. In a study 
with 98 patients age 18 years, ASA class I-III, sugamma-
dex was compared to neostigmine reversal (Blobner et al 
2007). Sugammadex 2.0 mg/kg or neostigmine 50 μg/kg 
along with glycopyrrolate 10 mcg/kg was administered at 
a TOF 2/4. The mean time to full reversal was 1.4 minutes 
for sugammadex and 17.6 min for neostigmine. Flockton 
compared sugammadex reversal of rocuronium effects to 
neostigmine reversal of the benzyl isoquinoline NMBA 
cis-atracurium. Sugammadex 2.0 mg/kg was delivered at 
TOF 2/4 after rocuronium 0.6 mg/kg in 34 patients. Neo-
stigmine 50 mcg/kg along with glycopyrrolate 10 μg/kg was 
delivered at TOF 2/4 after cis-atracurium 0.15 mg/kg in 39 
patients. The mean time to full reversal was 1.51 minutes 
for sugammadex compared to 2.85 minutes for neostigmine 
(Flockton et al 2007).
Phase III clinical trials have also explored the effects of 
sugammadex in pediatric and elderly patients, and in patients 
with renal, pulmonary, and cardiac disease. A study by Plaud Drug Design, Development and Therapy 2008:2 56
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investigated rocuronium-induced (0.6 mg/kg) neuromuscular 
blockade in 8 infants (age 28 days to 23 months), 24 children 
(age 2–11 years), 31 adolescents (age 12–17 years), and 28 
adults (age 18–65 years) anesthetized with propofol and opi-
oids or caudal anesthesia (Plaud et al 2007). When shallow 
neuromuscular block was conﬁ  rmed by TOF 2/4, sugammadex 
doses of 0.5–4.0 mg/kg were administered. A dose-dependent 
time to TOF ratio 0.9 was demonstrated in all groups except 
the infant group due to the low number of subjects. The median 
time to recovery was less than 3 minutes with sugammadex 
doses of 1.0, 2.0, and 4.0 mg/kg in all groups.
The efﬁ  cacy of sugammadex for the reversal of shallow 
rocuronium-induced neuromuscular blockade (TOF 2/4) was 
studied in 48 adult patients (age 18–64 years), 62 elderly 
(age 65–74 years), and 40 old elderly patients (age 75 
years) (McDonagh 2007). All patients received rocuronium 
0.6 mg/kg followed by sugammadex 2 mg/kg at a TOF 2/4. 
The mean time to recovery of the TOF ratio to 0.9 was 2.3 
minutes in the adult group, 2.6 minutes in the elderly group, 
and 3.6 minutes in the old elderly group. The estimated 
time to TOF 0.9 in all patients over 65 years of age was 2.9 
minutes versus 2.3 minutes in the adult group, a statistically 
signiﬁ  cant difference (p = 0.022).
The effectiveness of sugammadex for the reversal of 
rocuronium-induced neuromuscular blockade was assessed 
in 15 patients with impaired renal function (creatinine clear-
ance 30 mL/min) and 15 patients with normal renal func-
tion (creatinine clearance 80 mL/min) (Staals et al 2007). 
All patients were anesthetized with propofol and opioids, 
and had neuromuscular blockade induced with rocuronium 
0.6 mg/kg. At the reappearance of TOF 2/4, sugammadex 
2.0 mg/kg was administered. The mean time to recovery of 
TOF ratio to 0.9 was 2.0 minutes in the renal impaired group 
and 1.7 minutes in group with normal renal function. The 
authors reported no signs of recurarization or adverse effects, 
and concluded that sugammadex rapidly and completely 
reverses rocuronium-induced neuromuscular blockade in 
patients with normal or impaired renal function.
Patients with pulmonary disease were studied to examine 
the possible respiratory effects of sugammadex. Seventy-
seven patients 18 years or older, ASA class II-III, with 
a known history or diagnosis of pulmonary disease were 
anesthetized and administered rocuronium (0.6 mg/kg) 
(Amao et al 2007). At the end of surgery and reappearance 
of TOF 2/4, sugammadex 2.0 or 4.0 mg/kg was adminis-
tered. The mean time to recovery of the TOF ratio to 0.9 
was 1.8 minutes in the sugammadex 4.0 mg/kg group, 
and 2.1 minutes for the 2.0 mg/kg group. Two serious 
episodes of bronchospasm occurred that were considered 
possibly related to sugammadex, both of which were in 
the 4.0 mg/kg dose group. Both patients had a history of 
asthma. No alterations in respiratory rate or recurariza-
tion were observed in any patients. The authors concluded 
sugammadex was well tolerated and effective for the reversal 
of rocuronium-induced neuromuscular blockade in patients 
with pulmonary disease.
One hundred twenty-one patients with cardiac disease 
(NYHA class II-III, ASA class II-IV, age 36–90 years) under-
going elective non-cardiac surgery, were anesthetized and 
received rocuronium (Dahl et al 2007). At the reappearance 
of TOF 2/4, sugammadex 2.0 or 4.0 mg/kg was adminis-
tered. The mean time to a TOF ratio of 0.9 was found to be 
1.7 minutes with sugammadex 2.0 mg/kg and 1.4 minutes 
with the 4.0 mg/kg dose. The authors disclosed two serious 
adverse events (SAEs) relating to prolongation of the QTc 
interval in the placebo and sugammadex groups. “Of these, 
one case of QTc interval prolongation in each treatment 
group (placebo and sugammadex group) was considered by 
the investigator to be possibly related to study treatment”. 
Analysis of the mean QTc interval using the Fridericia 
correction (US Dept HHS 2005) was performed. Safe and 
effective use of sugammadex in cardiac patients was con-
cluded. However, the general anesthetics used in this study, 
which may cause QTc prolongation, were not disclosed in 
this preliminary report.
Reported adverse effects
Few adverse effects have been attributed to sugammadex. One 
study reported abdominal discomfort as “deﬁ  nitely related” 
to study drug (Suy et al 2007). Movement after sugammadex 
was observed in several studies which may be expected with 
rapid restoration of motor function and lighter anesthetic 
levels towards the conclusion of surgery (Sorgenfrei et al 
2006; de Boer et al 2007). Possible adverse effects reported in 
clinical trials include: erythema, alterations in taste and smell, 
coughing, dry mouth, tachycardia, bradycardia, pyrexia, 
dizziness, vomiting, hypotension, abnormal urine levels of 
N-acetyl-glucosamninidase, and QT interval prolongation 
(Gijsenbergh et al 2005; Shields et al 2006; Sorgenfrei et al 
2006; Dahl et al 2007). QT prolongation was ﬁ  rst observed 
by Rex but was considered not to be related to sugammadex 
(Rex et al 2005). An analysis by Vanacker determined that 
corrected QT prolongations, which were not arrhythmogenic, 
were likely to be due to the anesthetics sevoﬂ  urane and pro-
pofol (Vanacker et al 2007). A study by de Kam using the 
criteria of the International Conference on Harmonisation Drug Design, Development and Therapy 2008:2 57
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(ICH-E14) guidelines (Shah 2005) found that sugammadex 
doses up to 32 mg/kg were not associated with QT/QTc 
prolongation (de Kam et al 2007).The authors of a study in 
cardiac patients also reported that no QTc prolongations were 
related to sugammadex (Dahl et al 2007).
Inadvertent over dosage occurred in one clinical study, 
when sugammadex 40 mg/kg was administered instead of 
4.0 mg/kg, but this was not associated with any adverse 
effects and effective reversal of rocuronium was reported. 
(Molina et al 2007) Although most disclosed adverse effects 
have been expressed as only “possibly related” to the study 
drug, conclusive determination has yet to be made. It should 
be noted that some phase III studies have not been completed 
at the time of writing, and unknown side effects may exist. 
The results from one comparative study suggested that “the 
safety proﬁ  le of sugammadex was at least as good as that of 
neostigmine” (Jones et al 2007).
Metabolism and excretion
Sugammadex is biologically well tolerated. It does not 
undergo metabolism or breakdown and therefore does not 
affect blood sugar levels. It is excreted by the kidneys intact 
and has been found to increase the excretion of rocuronium 
molecules that it encapsulates (Sorgenfrei et al 2006). The 
renal excretion of sugammadex mirrors glomerular ﬁ  ltra-
tion rate (Gijsenbergh et al 2005) and it can be removed by 
dialysis (Hartman et al 2007).
Clinical implications of direct acting 
reversal by encapsulation
Intraoperative
The ability to reverse NMBAs directly and completely 
will allow the provision of continual profound neuromus-
cular blockade that may currently be inadvisable due to 
the limitations of cholinesterase inhibitor reversal agents. 
Multiple surgical specialties are likely to ﬁ  nd this beneﬁ  -
cial. With incomplete neuromuscular blockade, surgeons 
may encounter unnecessary difﬁ  culties. For example, 
those who require open access to abdominal cavities 
may struggle with retractors to improve visualization of 
structures. Others may ﬁ  nd patient extremities resistant 
to manipulation.
Patient attempts at spontaneous ventilation are evidence 
of incomplete neuromuscular blockade. Diaphragmatic 
excursion represents signiﬁ  cant return of neuromuscular 
function and closely correlates with motor function return 
of the abdominal rectus muscles. Motor function disrupts 
on optimal exposure and causes displacement of abdomi-
nal viscera. In contrast, profound neuromuscular blockade 
assures no diaphragmatic movement or abdominal rectus 
tone, and optimizes surgical access. Consistent profound 
neuromuscular blockade may also allow access through 
smaller incisions as muscular tension and contractions are 
eliminated as surgical hindrances.
Laproscopic procedures are assisted by assured patient 
immobility, as coughing or “bucking” under anesthesia 
increases the risk of organ injury and interferes with video 
imagining. Fracture reductions and manipulation of extremi-
ties may also be conducted with greater ease and speed in the 
absence of muscular tone or resistance. With the availability 
of sugammadex, surgical procedures requiring profound 
neuromuscular block may be accomplished without the risks 
associated with incomplete reversal by cholinesterase inhibi-
tors. That is, by means of its rapid and complete reversal 
of rocuronium and vecuronium, sugammadex will allow 
surgeons to operate with profound neuromuscular blockade 
up to and including wound closure.
Neuromuscular monitoring
In light of the effectiveness of SRBAs, the question of 
continued use of neuromuscular monitoring has been raised 
(Kopman 2006; Naguib 2007). Neuromuscular monitoring 
should be used whenever neuromuscular blocking agents 
are administered. In the interests of improving vigilance, 
and because of concerns about potentially insufﬁ  cient 
sugammadex doses, we suggest the continued use of nerve 
stimulators to assess the degree of neuromuscular blockade. 
Eleveld described a scenario in which initial recovery to 
a TOF ratio of 0.9 quickly deteriorated to 0.3 due to an 
insufﬁ  cient dose of sugammadex (0.5 mg/kg) delivered 
for the reversal of profound rocuronium-induced neuro-
muscular blockade in a dose-ﬁ  nding study (Eleveld et al 
2007). Consistent and effective dosages based on degree of 
blockade will be determined, however, individual variabil-
ity and under-dosing may allow recurarization such as that 
reported by Eleveld. Clinical assessment and neuromuscular 
monitoring should remain a mainstay of anesthesia practice 
(Eriksson 2003).
Summary
An opportunity is emerging that will allow profound neuro-
muscular blockade during surgery with full and immediate 
reversal upon conclusion. Reversal of neuromuscular block-
ade with the novel agent sugammadex is likely to increase 
the speed of patient recovery from anesthesia and improve 
time to discharge. Delivery of a safer, more effective drug Drug Design, Development and Therapy 2008:2 58
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for reversal of NMBA will also provide additional beneﬁ  ts. 
For example, the assurance of full reversal of neuromus-
cular blockade will allow improved conditions for surgery 
and, possibly, improved patient recovery. The rapid return 
of neuromuscular function achieved by sugammadex may 
also facilitate rapid sequence intubation using the non-
depolarizing NMBA rocuronium, and play a role in the 
management of the “cannot intubate, cannot ventilate sce-
nario. Rescue of residual paralysis resulting from incomplete 
reversal by cholinesterase inhibitors may also be performed 
quickly. Differential diagnosis of low level residual paralysis 
versus other compromising factors may also be achieved 
with sugammadex.
Patient outcome studies comparing conventional NMBA 
reversal with cholinesterase inhibitors to reversal by means 
of CD encapsulation are needed to determine the potential 
beneﬁ  ts of sugammadex beyond effective and immedi-
ate NMBA reversal. Complete control of neuromuscular 
blockade with immediate reversibility will allow anes-
thetists to offer surgeons optimal conditions that are not 
always achieved at present. A full appreciation of SRBA 
pharmacology will become known with continued clinical 
study, but, the successful outcomes of studies to date appear 
to be heralding in a new era in neuromuscular blockade 
management.
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